Rheumatoid Arthritis

Percentage of Newly Diagnosed Patients With Rheumatoid Arthritis Starting Biologic DMARDs Who Attained Near Remission or Low Severity Disease Activity (2016-2020)

Percentage of Newly Diagnosed Patients With Rheumatoid Arthritis Starting Biologic DMARDs Who Attained Near Remission or Low Severity Disease Activity (N=786)

2015-2019

  1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 Jan;68(1):1-25.

American College of Rheumatology guidelines for rheumatoid arthritis recommend a treat-to-target strategy with the target being low disease activity using an established disease activity measure¹. We assessed disease activity using RAPID3, a validated patient-reported composite measure of disease activity. Patients with newly diagnosed rheumatoid arthritis started on a biologic DMARD between 2015 and 2019 were reviewed. We considered success as a RAPID3 score of <2.3 (near remission and low severity). 786 rheumatoid arthritis patients were started on a biologic DMARD during 2015-2019. Of these 36.8% achieved a RAPID3 score of <2.3. The percent of patients in remission or near remission declined from a high of 42.6 % in 2016 to 25% in 2019. A significant number of patients remained in moderate or high severity based on RAPID3 scores, indicating the need to monitor and apply treat-to-target strategies in rheumatoid arthritis.